Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Brent seems pretty upbeat on this one.
View:
Post by whitenorth72 on Jun 11, 2024 4:38pm

Brent seems pretty upbeat on this one.

Comment by biggdogg on Jun 11, 2024 6:34pm
Its a billion$ molecule, He is at MArs conference, according to LinkedIn, rubbing shoulders with Big Pharma, The folks at Mars are in for an awakening, this molecule is revolutionary.
Comment by postie1 on Jun 11, 2024 7:24pm
If this molecule can carry other drugs more affectively, then how much will it be worth to a bigger company? One thing VM might have going for it in case of a lowball offer is us. A lot of shares are probably held by small investors and from the way level 2 jumps to over  $1 it does not seem like people are willing to let it go cheap. Very few shares are being put up for sale and I question ...more  
Comment by postie1 on Jun 11, 2024 7:52pm
Who knows but a bigger company could provide financing for a chunk of VM?
Comment by WarrantOfficer on Jun 12, 2024 8:12am
Personally, this is not my first choice as a financing avenue. Selling part of the company equates to reduced profits. 
Comment by WarrantOfficer on Jun 12, 2024 8:22am
Indeed an industry changer. One of my main concerns is Voyageurs consistent lack of expedited forward traction. An international corp will step in with a bank full of dollars while Voyageur fumbles for financing. RainCage will not sit idle. 
Comment by JrOGInvestor on Jun 13, 2024 5:36am
We shall see how well he pitches it in Toronto. He is a featured speaker at the MaRS Impact Health Conference today discussing Innovative Radiology Drug Developmennt, Product Launch, and Revenue Pathways.
Comment by oldtrouf on Jun 13, 2024 7:46am
You folks better put in your buy order ASAP.  Once Brent makes his speach today, everyoone in the room will be on their phone to their broker lining up to buy shares at any price.  That wall at .08 will go down like a hot butter with a knife.   This is the exact venue VM needed to get the word out. Watch and learn.   
Comment by WarrantOfficer on Jun 13, 2024 8:36am
By the lunker fish gods oldtrouf. A tint of optimism? 
Comment by postie1 on Jun 13, 2024 11:54am
Maybe it is time to sell !
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1